Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Vaginal candidiasis is common during pregnancy. Although intravaginal formulations of topical azole antifungals are first-line treatment for pregnant women, oral fluconazole is often used despite limited safety information. OBJECTIVE: To study the association between oral fluconazole exposure during pregnancy and the risk of spontaneous abortion and stillbirth. DESIGN, SETTING, AND PARTICIPANTS: Nationwide register-based cohort study in Denmark, 1997-2013. From a cohort of 1,405,663 pregnancies, oral fluconazole-exposed pregnancies were compared with up to 4 unexposed pregnancies matched on propensity score, maternal age, calendar year, and gestational age (based on gestational age at first day of treatment with eligible controls surviving through this date). To test for confounding by indication, pregnancies exposed to intravaginal formulations of topical azoles were used as an additional comparator group. EXPOSURES: Filled prescriptions for oral fluconazole were obtained from the National Prescription Register. MAIN OUTCOMES AND MEASURES: Hazard ratios (HRs) for spontaneous abortion and stillbirth, estimated using proportional hazards regression. RESULTS: Among 3315 women exposed to oral fluconazole from 7 through 22 weeks' gestation, 147 experienced a spontaneous abortion, compared with 563 among 13,246 unexposed matched women. There was a significantly increased risk of spontaneous abortion associated with fluconazole exposure (HR, 1.48; 95% CI, 1.23-1.77). Among 5382 women exposed to fluconazole from gestational week 7 to birth, 21 experienced a stillbirth, compared with 77 among 21,506 unexposed matched women. There was no significant association between fluconazole exposure and stillbirth (HR, 1.32 [95% CI, 0.82-2.14]). Using topical azole exposure as the comparison, 130 of 2823 women exposed to fluconazole vs 118 of 2823 exposed to topical azoles had a spontaneous abortion (HR, 1.62 [95% CI, 1.26-2.07]); 20 of 4301 women exposed to fluconazole vs 22 of 4301 exposed to topical azoles had a stillbirth (HR, 1.18 [95% CI, 0.64-2.16]). CONCLUSIONS AND RELEVANCE: In this nationwide cohort study in Denmark, use of oral fluconazole in pregnancy was associated with a statistically significant increased risk of spontaneous abortion compared with risk among unexposed women and women with topical azole exposure in pregnancy. Until more data on the association are available, cautious prescribing of fluconazole in pregnancy may be advisable. Although the risk of stillbirth was not significantly increased, this outcome should be investigated further.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Intrauterine infection and preterm delivery
Goldenberg, R. L., Hauth, J. C., & Andrews, W. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422007 · Cited by 2,548
Incidence of early loss of pregnancy
Wilcox, A. J., Weinberg, C. R., O'Connor, J. F., Baird, D. D., Schlatterer, J. P., Canfield, R. E., Armstrong, E. G., & Nisula, B. C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807283190401 · Cited by 2,354
Austin, P. C. (2009) · Biometrical Journal · doi:10.1002/bimj.200810488 · Cited by 769
Fluconazole-induced congenital anomalies in three infants
Pursley, T. J., Blomquist, I. K., Abraham, J., Andersen, H. F., & Bartley, J. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.336 · Cited by 246
Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy
Cotch, M. F., Hillier, S. L., Gibbs, R. S., & Eschenbach, D. A. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)80028-8 · Cited by 198
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Chang, C. C., Harrison, T. S., Bicanic, T. A., Chayakulkeeree, M., Sorrell, T. C., Warris, A., Hagen, F., Spec, A., Oladele, R., Govender, N. P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00731-4 · Cited by 326
Sherrard, J., Wilson, J., Donders, G., Mendling, W., & Jensen, J. S. (2018) · International Journal of STD & AIDS · doi:10.1177/0956462418785451 · Cited by 297
Guideline: Vulvovaginal Candidosis (AWMF 015/072, Level S2k)
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., Ruhnke, M., Schaller, M., Schaefer, A. P. A., Sustr, V., et al. (2021) · Mycoses · doi:10.1111/myc.13248 · Cited by 184
Nyirjesy, P., Brookhart, C., Lazenby, G., Schwebke, J., & Sobel, J. D. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1057 · Cited by 149
Brand, S. R., Degenhardt, T. P., Person, K., Sobel, J. D., Nyirjesy, P., Schotzinger, R. J., & Tavakkol, A. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.03.001 · Cited by 78
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Wu, X., Zhang, S., Xu, X., Shen, L., Xu, B., Qu, W., Zhuang, W., Locock, K., Deighton, M., & Qu, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02592 · Cited by 23
Metadata
- Authors
- Mølgaard-Nielsen, D., Svanström, H., Melbye, M., Hviid, A., & Pasternak, B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-01-05
- Volume
- 315
- Issue
- 1
- Pages
- 58
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2229168473
- Cited by
- 108
- References
- 6
- FWCI
- 12.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.